FDA Approves First Targeted Therapy for Pancreatic Cancer

The FDA has granted approval for Daraxonrasib, an oral drug representing the first targeted therapy for pancreatic cancer. This medication specifically inhibits RAS proteins, which are implicated in over 90% of pancreatic cancer cases. Clinical trials indicated that patients treated with Daraxonrasib lived an average of seven months longer than those receiving chemotherapy alone, marking a significant advancement for a highly aggressive cancer.